- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01175109
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
December 26, 2012 updated by: Deric M Park MD
Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
This is a multi-center study to assess the safety and to determine the maximum tolerated dose of the combination of imatinib and LBH589 in patients with newly diagnosed and recurrent chordoma.
For the recurrent population, those patients that do not require immediate surgical resection will be eligible.
Patients will be treated with 4 cycles, followed by surgical resection if possible.
If indicated, surgery may take place prior to the completion of 4 cycles.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University of Virginia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients greater than or equal to 18 years of age.
- Histologically documented diagnosis of chordoma
- At least one measurable site of disease (as defined by Response Evaluation Criteria in Solid Tumors, see Appendix 3).
- Performance status 0,1, or 2 (ECOG) (see Section 6)
Patients must have adequate bone marrow and end organ function, as defined as the following:
- WBC > 3.0 x 109/L
- ANC > 1.5 x 109/L,
- Platelets > 100 x 109/L
- Hemoglobin > 10 gm/dl
- Total bilirubin < 1.5 x ULN (Does not apply to patients with isolated hyperbilirubinemia (e.g., Gilbert's disease) grade <3.
- AST/SGOT and ALT/SGPT < 2.5 x UNL
- Serum creatinine ≤ 2.5 x ULN or 24 hr creatinine clearance ≥ 50ml/min
- Serum albumin ≤ 3g/dL
- Serum amylase and lipase ≤ 1.5 x ULN
- Alkaline phosphatase ≤ 2.5 x ULN
Patients must have the following laboratory values (WNL = within normal limits at the local institution lab) or corrected to within normal limits with supplements prior to the first dose of study medication:
- Potassium (WNL)
- Magnesium (WNL)
- Phosphorus (WNL)
- Calcium (WNL)
- Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
- A scan should be performed within 14 days prior to registration. The same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement.
- Patients must have an interval of greater than or equal to 3 months from the completion of radiation therapy to study entry.
- Patients must be willing to participate in the pharmacokinetic studies.
- Written, voluntary informed consent.
Exclusion Criteria:
- Patient has received any other investigational agents within 28 days of first day of study drug dosing for treatment of chordoma, unless the disease is rapidly progressing. Patients who have been previously treated with imatinib or LBH589 are ineligible.
- Patients must not be on enzyme inducing anticonvulsants or valproic acid, a seizure medication with HDAC inhibition activity.
- Patient is < 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
- Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
Impaired cardiac function including any one of the following:
- Inability to monitor the QT/QTc interval on ECG
- Long QT syndrome or a known family history of long QT syndrome.
- Clinically significant resting brachycardia (<50 beats per minute)
- QTc > 450 msec on baseline ECG (using the QTcF formula). If QTcF >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc
- Myocardial infarction within 12 months prior to starting study
- Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension)
- History of or presence of clinically significant ventricular or atrial tachyarrhythmias
- Female patients who are pregnant or breast-feeding.
- Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
- Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
- Patient has known brain metastasis
- Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
- Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C)prior to study entry, unless the disease is rapidly progressing.
- Patient receiving concurrent treatment with warfarin.
- Patient previously received radiotherapy to > 25 % of the bone marrow
- Patient had a major surgery within 2 weeks prior to study entry.
- Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
- Patients may not be receiving any other investigational agents.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to imatinib or LBH589 used in study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Escalating doses of imatinib and LBH589
Study will incorporate a "3+3" dose escalation design.
|
Escalating doses of imatinib and LBH589 will be administered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of dose limiting toxicities
Time Frame: At time of study drug discontinuation
|
At time of study drug discontinuation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor response
Time Frame: Week 7
|
Tumor response will be evaluated using the RECIST criteria
|
Week 7
|
Tumor response
Time Frame: Week 12
|
Tumor response will be evaluated using the RECIST criteria.
|
Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Deric M Park, MD, University of Virginia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2011
Primary Completion (Anticipated)
December 1, 2013
Study Completion (Anticipated)
December 1, 2013
Study Registration Dates
First Submitted
July 28, 2010
First Submitted That Met QC Criteria
August 3, 2010
First Posted (Estimate)
August 4, 2010
Study Record Updates
Last Update Posted (Estimate)
December 27, 2012
Last Update Submitted That Met QC Criteria
December 26, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15120
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chordoma
-
Jonsson Comprehensive Cancer CenterBristol-Myers SquibbCompletedChordoma | Metastatic Chordoma | Unresectable Chordoma | Locally Advanced ChordomaUnited States
-
M.D. Anderson Cancer CenterRecruitingChordoma | Metastatic Chordoma | Unresectable ChordomaUnited States
-
Institut CurieActive, not recruitingSkull Base Chordoma | Vertebral ChordomaFrance
-
Heidelberg UniversityActive, not recruiting
-
Huashan HospitalBoehringer IngelheimNot yet recruiting
-
Xuanwu Hospital, BeijingRecruiting
-
CNAO National Center of Oncological HadrontherapyDept. of Electronics, Informatics, Bioengineering, Politecnico di Milano,...Recruiting
-
Massachusetts General HospitalM.D. Anderson Cancer Center; National Cancer Institute (NCI)Active, not recruitingChordoma of Sacrum | Chordoma of Spine | Chordoma of Base of Skull | Chondrosarcoma of the Spine | Chondrosarcoma of the SacrumUnited States
-
National Cancer Institute (NCI)RecruitingGenes | Sporadic ChordomaUnited States
-
Hospices Civils de LyonRecruitingMalignant Tumors as Chordoma, Adenoid Cystic Carcinoma and SarcomaFrance
Clinical Trials on Imatinib + LBH589
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
Novartis PharmaceuticalsTerminatedLeukemia-Lymphoma, Adult T-Cell | Cutaneous T-Cell LymphomaJapan
-
Abdullah KutlarSecura Bio, Inc.RecruitingSickle Cell DiseaseUnited States
-
Centre Leon BerardCompletedGastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene MutationFrance
-
Scandinavian Sarcoma GroupCompleted
-
Mayo ClinicNational Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...NovartisTerminatedBrain Metastasis | Recurrent Glioma | High-grade MeningiomaUnited States
-
Sarit AssoulineNovartisRecruitingChronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | Chronic Myeloid Leukemia, BCR/ABL-PositiveCanada
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myeloid LeukemiaChina
-
Seoul St. Mary's HospitalNovartisUnknownChronic Myeloid LeukemiaKorea, Republic of